Not the joints, on this evidence. Among 1,017 matched pairs with type 2 diabetes, rheumatoid arthritis and obesity, semaglutide was associated with major adverse cardiac and cerebrovascular events in 12.7% against 16.5%, a hazard ratio of 0.75 (95% CI 0.60 to 0.94) [1]. The composite moved because heart failure moved, at 8.9% against 12.5%, while death, heart attack and stroke showed no significant difference at all. Nothing in the study measured joint disease. The inflammation these drugs are shown to lower is a blood marker: high-sensitivity CRP fell 37.8% at 104 weeks in SELECT [2].
Rheumatoid arthritis makes exercise painful and weight management harder, and it adds chronic inflammation on top, so cardiovascular risk in this group is elevated for several reasons at once. A target trial emulation in a US database asked whether semaglutide changes that, comparing 1,017 matched pairs who started it against other second-line glucose-lowering drugs[1]. Everyone was free of prior stroke, heart failure and coronary events, making this a primary-prevention question, which is a harder one than the established heart failure evidence addresses.
The composite outcome separated. Major adverse cardiovascular and cerebrovascular events occurred in 12.7% against 16.5%, a hazard ratio of 0.75 (95% CI 0.60–0.94, P = .01).
Heart failure is also the component where a weight drug has the clearest non-vascular route to an effect. It is diagnosed substantially on symptoms, breathlessness on exertion chief among them, and removing a tenth of someone's body weight changes how far they can walk before they are short of breath. A real reduction in cardiac strain and a change in what gets coded both produce this number, and two years of follow-up in a thousand pairs cannot separate them. The same detection problem, with the two endpoints disagreeing rather than agreeing, appears in the carpal tunnel cohort.
What happens when a joint is measured directly
Rheumatoid arthritis has not been measured that way, and the nearest thing is osteoarthritis. Ninety-three adults with knee osteoarthritis started semaglutide in routine rheumatology care and 88 completed six months, over which mean weight fell 10.88 kg, pain fell 2.47 points and the WOMAC total fell 22.50 points [3]. C-reactive protein fell 2.67 mg/L and the sedimentation rate 7.62 mm/h. There was no untreated comparison group, and the authors state in their own methods that the changes are therefore non-causal, which is rarer than the result and worth more. Osteoarthritis is mechanical and rheumatoid arthritis is autoimmune, so this is an adjacent measurement rather than a stand-in, and the randomized version of it sits in the knee pain trial.
Escalation to a disease-modifying antirheumatic drug was lower as well, 16.6% against 21.6% (HR 0.75, 95% CI 0.60–0.90). The temptation is to read that as less active arthritis, and it should be resisted for the reason set out in the Crohn's disease cohort. There, a lower rate of recorded biologic use could not be distinguished from a change in prescribing patterns. A claims database sees the prescription, not the joint.
The authors ask for prospective work and apply a Bonferroni correction for their secondary comparisons, both of which are the right instincts. What survives is a plausible, modest, single-component finding in a group that gets studied rarely. It is also a reminder that the weight itself does things a composite endpoint will happily absorb, including to muscle, as covered in what these drugs do to muscle.